Showing results (51-60 of 59) with videos related to
Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Frontiers in Bioscience : a Journal and Virtual Library|December 5, 2000
Cell-cycle dysregulation in breast cancer: breast cancer therapies targeting the cell cycleB T Zafonte, J Hulit, D F Amanatullah, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 1996
Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphomaJ A Sparano, P H Wiernik, X Hu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1993
Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanomaJ A Sparano, R I Fisher, M Sunderland, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanomaM B Atkins, K R O'Boyle, J A Sosman, et al.Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|October 1, 1994
Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumorsJ A Sparano, R I Fisher, G R Weiss, et al.Breast Cancer Research and Treatment|December 28, 2011
Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivoB Ramaswamy, W Fiskus, B Cohen, et al.Breast Cancer Research and Treatment|February 2, 2018
Refined estimates of local recurrence risks by DCIS score adjusting for clinicopathological features: a combined analysis of ECOG-ACRIN E5194 and Ontario DCIS cohort studiesE Rakovitch, R Gray, F L Baehner, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 9, 2018
Pre-surgical trial of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer: a New York Cancer Consortium trialK Kalinsky, J A Sparano, X Zhong, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 30, 2015
Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphomaS K Barta, M S Samuel, X Xue, et al.Pageof 6